Osteoporosis treatment: recent developments and ongoing challenges

Riggs, 2003, Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice, N Engl J Med, 348, 618, 10.1056/NEJMra022219

Khosla, 2012, Benefits and risks of bisphosphonate therapy for osteoporosis, J Clin Endocrinol Metab, 97, 2272, 10.1210/jc.2012-1027

Kearns, 2008, Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease, Endocr Rev, 29, 155, 10.1210/er.2007-0014

Neer, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904

Miller, 2016, Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial, JAMA, 316, 722, 10.1001/jama.2016.11136

Cosman, 2016, Romosozumab treatment in postmenopausal women with osteoporosis, N Engl J Med, 375, 1532, 10.1056/NEJMoa1607948

Mullard, 2016, Merck & Co. drops osteoporosis drug odanacatib, Nat Rev Drug Discov, 15, 445, 10.1038/nrd.2016.207

Kim, 2016, Impact of the US Food and Drug Administration's safety-related announcements on the use of bisphosphonates after hip fracture, J Bone Miner Res, 31, 1535, 10.1002/jbmr.2832

Albright, 1940, Post-menopausal osteoporosis, Trans Assoc Am Physicians, 55, 298

Khosla, 2008, Osteoporosis in men, Endocr Rev, 29, 441, 10.1210/er.2008-0002

Lindsay, 1976, Long-term prevention of postmenopausal osteoporosis by oestrogen, Lancet, i, 1038, 10.1016/S0140-6736(76)92217-0

Lufkin, 1992, Treatment of postmenopausal osteoporosis with transdermal estrogen, Ann Intern Med, 117, 1, 10.7326/0003-4819-117-1-1

Cauley, 2006, Effect of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial, JAMA, 290, 1729, 10.1001/jama.290.13.1729

Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321

Ettinger, 2004, Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial, Obstet Gynecol, 104, 443, 10.1097/01.AOG.0000137833.43248.79

Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial, JAMA, 282, 637, 10.1001/jama.282.7.637

Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA, 295, 2727, 10.1001/jama.295.23.joc60074

Lindsay, 2009, Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, Fertil Steril, 92, 1045, 10.1016/j.fertnstert.2009.02.093

Austin, 1981, Calcitonin: physiology and pathophysiology, N Engl J Med, 304, 269, 10.1056/NEJM198101293040505

Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence Of Osteoporotic Fractures study, Am J Med, 109, 267, 10.1016/S0002-9343(00)00490-3

Russell, 2011, Bisphosphonates: the first 40 years, Bone, 49, 2, 10.1016/j.bone.2011.04.022

Russell, 2008, Mechanisms of action of bisphosphonates: similarities and differences and their potential influences on clinical efficacy, Osteoporos Int, 19, 733, 10.1007/s00198-007-0540-8

Shane, 2014, Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone Mineral Research, J Bone Miner Res, 29, 1, 10.1002/jbmr.1998

Khosla, 2007, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res, 22, 1479, 10.1359/jbmr.0707onj

Whitaker, 2012, Bisphosphonates for osteoporosis—where do we go from here?, N Engl J Med, 366, 2048, 10.1056/NEJMp1202619

Albright, 1934, Hyperparathyroidism. A common and polymorphic condition as illustrated by seventeen proved cases from one clinic, JAMA, 102, 1276, 10.1001/jama.1934.02750160010003

Reeve, 1976, Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis, Lancet, 1, 1035, 10.1016/S0140-6736(76)92216-9

Vahle, 2004, Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose, Toxicol Pathol, 32, 426, 10.1080/01926230490462138

Andrews, 2012, The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the last 7 years, J Bone Miner Res, 27, 2429, 10.1002/jbmr.1768

Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3

Bucay, 1998, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, 1260, 10.1101/gad.12.9.1260

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493

Meunier, 2004, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis, N Engl J Med, 350, 459, 10.1056/NEJMoa022436

Lacey, 2012, Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab, Nat Rev Drug Discov, 11, 401, 10.1038/nrd3705

Hamersma, 2003, The natural history of sclerostosis, Clin Genet, 63, 192, 10.1034/j.1399-0004.2003.00036.x

van Lierop, 2013, Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers, J Bone Miner Res, 28, 848, 10.1002/jbmr.1794

Baron, 2013, WNT signaling in bone homeostasis and disease: from human mutations to treatments, Nat Med, 19, 179, 10.1038/nm.3074

Teitelbaum, 2007, Osteoclasts: what do they do and how do they do it?, Am J Pathol, 170, 427, 10.2353/ajpath.2007.060834

Gelb, 1996, Pycnodysostosis, a lysosomal storage disease caused by cathepsin K deficiency, Science, 273, 1236, 10.1126/science.273.5279.1236

Gowen, 1999, Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization, J Bone Miner Res, 14, 1654, 10.1359/jbmr.1999.14.10.1654

Bone, 2015, Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial, Osteoporos Int, 26, 699, 10.1007/s00198-014-2944-6

Canalis, 2007, Mechanisms of anabolic therapies for osteoporosis, N Engl J Med, 357, 905, 10.1056/NEJMra067395

Hattersley, 2016, Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling, Endocrinology, 157, 141, 10.1210/en.2015-1726

Leder, 2015, Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 100, 697, 10.1210/jc.2014-3718

Baron, 2012, Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives, J Clin Endocrinol Metab, 97, 311, 10.1210/jc.2011-2332

Baron, 2007, Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton, Endocrinology, 148, 2635, 10.1210/en.2007-0270

Li, 2008, Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength, J Bone Miner Res, 23, 860, 10.1359/jbmr.080216

Lim, 2017, Profile of romosozumab and its potential in the management of osteoporosis, Drug Des Devel Ther, 11, 1221, 10.2147/DDDT.S127568

Lewiecki, 2014, Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases, Ther Adv Musculoskelet Dis, 6, 48, 10.1177/1759720X13510479

McClung, 2014, Romosozumab in postmenopausal women with low bone mineral density, N Engl J Med, 370, 412, 10.1056/NEJMoa1305224

Kahn, 2014, Can we safely target the WNT pathway?, Nat Rev Drug Discov, 13, 513, 10.1038/nrd4233

Florio, 2016, A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair, Nat Commun, 7, 11505, 10.1038/ncomms11505

Khosla, 2012, Odanacatib: location and timing are everying, J Bone Miner Res, 27, 506, 10.1002/jbmr.1541

Costa, 2011, Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis, Nat Rev Rheumatol, 7, 447, 10.1038/nrrheum.2011.77

Langdah, 2012, Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study, J Bone Miner Res, 27, 2251, 10.1002/jbmr.1695

Khosla, 2016, A crisis in the treatment of osteoporosis, J Bone Miner Res, 31, 1485, 10.1002/jbmr.2888

Eisman, 2012, Making the first fracture the last fracture: ASBMR Task Force on Secondary Fracture Prevention, J Bone Miner Res, 27, 2039, 10.1002/jbmr.1698

Kolata

Black, 2016, Clinical practice. Postmenopausal osteoporosis, N Engl J Med, 374, 254, 10.1056/NEJMcp1513724

Khosla, 2017, Addressing the crisis in the treatment of osteoporosis: a path forward, J Bone Miner Res, 32, 424, 10.1002/jbmr.3074

McKenna, 2013, Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by extending femur length, J Clin Densitom, 16, 579, 10.1016/j.jocd.2013.06.004

Mahjoub, 2013, Incidence and characteristics of atypical femoral fractures: clinical and geometrical data, J Bone Miner Res, 31, 767, 10.1002/jbmr.2748

Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial, JAMA, 296, 2927, 10.1001/jama.296.24.2927

Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res, 27, 243, 10.1002/jbmr.1494

Adler, 2016, Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res, 31, 16, 10.1002/jbmr.2708

Bone, 2017, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, Lancet Diabetes Endocrinol, 5, 513, 10.1016/S2213-8587(17)30138-9

Leder, 2015, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial, Lancet, 386, 1147, 10.1016/S0140-6736(15)61120-5

Tankó, 2016, Does activin receptor blockade by bimagrumab (BYM338) pose detrimental effects on bone healing in a rat fibula osteotomy model?, Calcif Tissue Int, 99, 310, 10.1007/s00223-016-0148-0